Broadly neutralizing antibodies (bNAbs) represent a promising approach to prevent and
treat HIV-1 infection. However, viral escape through mutation of the HIV-1 envelope …

AIDS is a preventable disease. Nevertheless, according to UNAIDS, 2.1 million individuals
were infected with HIV-1 in 2015 worldwide. An effective vaccine is highly desirable. Most …

Targeting germline (gl-) precursors of broadly neutralizing antibodies (bNAbs) is
acknowledged as an important strategy for HIV-1 vaccines. The VRC01-class of bNAbs is …

The HIV genome encodes a small number of viral proteins (ie, 16), invariably establishing
cooperative associations among HIV proteins and between HIV and host proteins, to invade …

The maternal immune system protects developing offspring against pathogens before birth
via transplacental transfer and after birth through secreted milk. This transferred maternal …

Broadly neutralizing antibodies (bNAbs), able to prevent viral entry by diverse global
viruses, are a major focus of HIV vaccine design, with data from animal studies confirming …

The induction by vaccination of broadly neutralizing antibodies (bNAbs) capable of
neutralizing various HIV-1 viral strains is challenging, but understanding how a subset of …

Elicitation of antibodies that neutralize the tier-2 neutralization-resistant isolates that typify
HIV-1 transmission has been a long-sought goal. Success with prefusion-stabilized …

Since their discovery, antibodies capable of broad neutralisation have been at the forefront
of HIV-1 research and are of particular interest due to in vivo passive transfer studies …

Antigenic mimicry is a fundamental tenet of structure-based vaccinology. Vaccine strategies
for the human immunodeficiency virus type 1 (HIV-1) focus on the mimicry of its envelope …